Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ductal Breast Carcinoma In Situ|Lobular Breast Carcinoma In Situ|Stage 0 Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer
Interventions: DRUG: Telapristone Acetate|OTHER: Placebo|DRUG: Telapristone Acetate|OTHER: Placebo|OTHER: Laboratory Biomarker Analysis|OTHER: Questionnaire Administration
Sponsor: Northwestern University
Collaborators: National Cancer Institute (NCI)